ViVac Demonstrates Tumor-Targeted Delivery and In Vivo RNA Expression

ViVac has achieved a major scientific milestone with confirmed in vivo RNA expression and tumor-targeted delivery using its proprietary synthetic RNA–Lipid Nanoparticle (LNP) platform. The data validate the company’s vision of combining viral potency with RNA-level safety to create a new generation of localized cancer immunotherapies.

The results demonstrate that ViVac’s engineered RNA replicons can safely express within tumor cells while remaining self-limiting — a breakthrough that addresses the key safety limitations of oncolytic viruses and the efficacy gaps of conventional mRNA therapies.

“Achieving this level of controlled RNA expression inside tumors is a crucial step toward clinical translation,” said Dr. Ron Lahav, Chief Technology Officer at ViVac. “Our results show that we can harness viral-like immune activation without the risks associated with live viral therapies.”

The company continues to advance its lead oncology programs in melanoma, glioblastoma, and ovarian cancer, while optimizing its scalable RNA manufacturing and delivery platform. ViVac’s IND submission is targeted for 2026.